Related Experiment Videos
Inflammation and lipid-lowering treatment
1Department of Medicine, Baylor College of Medicine, 6565 Fannin, MS A-601, Houston, Texas 77030, USA.
Insights
Leukocyte adhesion molecules (CAMs) are key in atherosclerosis development and plaque instability. Soluble CAM levels, elevated in at-risk patients, decrease with lipid-lowering treatments, suggesting their use as novel inflammation markers.
Area of Science:
- Cardiovascular Science
- Immunology
- Biochemistry
Background:
- Leukocytes are central to atherogenesis, plaque instability, and thrombosis.
- Leukocyte-endothelial cell adhesion molecules (CAMs) regulate leukocyte-vessel wall interactions.
- Elevated soluble CAMs are observed in dyslipidemia and other atherosclerosis risk factors.
Purpose of the Study:
- To investigate the role of soluble CAMs as markers in atherosclerosis.
- To assess the impact of lipid-modifying therapy on soluble CAM levels.
- To explore novel inflammation markers for identifying high-risk individuals and evaluating treatment efficacy.
Main Methods:
- Analysis of leukocyte-endothelial cell adhesion molecules (CAMs).
- Measurement of soluble CAM levels in patients with dyslipidemia and other risk factors.
- Evaluation of changes in soluble CAM levels following lipid-modifying therapy.
Main Results:
- Soluble CAM levels are elevated in individuals with dyslipidemia and other cardiovascular risk factors.
- Lipid-modifying therapy effectively reduces soluble CAM levels.
- CAMs show potential as indicators of inflammatory processes in atherosclerosis.
Conclusions:
- Soluble CAMs are implicated in the pathogenesis of atherosclerosis.
- Reduced soluble CAM levels following treatment suggest therapeutic efficacy.
- Novel CAM markers may aid in identifying individuals at high risk for cardiovascular events and monitoring antiatherosclerotic therapies.
Abstract:
Leukocytes play a critical role in both the initial steps of atherogenesis and the late events of plaque instability and thrombosis. Leukocyte-endothelial cell adhesion molecules (CAMs) modulate the interaction between circulating leukocytes and the vessel wall. Levels of soluble CAMs are increased in patients with dyslipidemia or other risk factors, and levels can be reduced by lipid-modifying therapy. Novel markers of inflammation and atherosclerosis may be useful to identify high-risk individuals and to assess the efficacy of antiatherosclerotic therapy.